» Articles » PMID: 35514962

B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients

Abstract

Background: Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients.

Methods: B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy.

Results: Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were naïve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders.

Summary: Substantial repopulation of the naïve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses.

Citing Articles

Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring.

Xu P, Li Y, Zhuang X, Yue L, Ma Y, Xue W Immunol Res. 2024; 72(5):1185-1197.

PMID: 39254909 DOI: 10.1007/s12026-024-09521-5.


Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.

Priddey A, Chen-Xu M, Cooper D, MacMillan S, Meisl G, Xu C Front Immunol. 2024; 14:1296148.

PMID: 38259440 PMC: 10800570. DOI: 10.3389/fimmu.2023.1296148.


COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series.

Colmegna I, Valerio V, Amiable N, Useche M, Rampakakis E, Flamand L RMD Open. 2023; 9(4).

PMID: 38030231 PMC: 10689388. DOI: 10.1136/rmdopen-2023-003400.


Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant Recipients.

Stai S, Fylaktou A, Kasimatis E, Xochelli A, Lioulios G, Nikolaidou V Vaccines (Basel). 2023; 11(10).

PMID: 37896986 PMC: 10611345. DOI: 10.3390/vaccines11101583.


Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients.

Seree-Aphinan C, Ratanapokasatit Y, Suchonwanit P, Rattanakaemakorn P, O-Charoen P, Pisitkun P Front Immunol. 2023; 14:1138765.

PMID: 37006291 PMC: 10050596. DOI: 10.3389/fimmu.2023.1138765.


References
1.
Blanco E, Perez-Andres M, Arriba-Mendez S, Contreras-Sanfeliciano T, Criado I, Pelak O . Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J Allergy Clin Immunol. 2018; 141(6):2208-2219.e16. DOI: 10.1016/j.jaci.2018.02.017. View

2.
Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D . SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021; 80(10):1345-1350. DOI: 10.1136/annrheumdis-2021-220781. View

3.
Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

4.
Hsu C, Ko C, Wang J, Hsu T, Lin C . Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther. 2019; 21(1):211. PMC: 6790041. DOI: 10.1186/s13075-019-1997-5. View

5.
Jennette J, Falk R, Bacon P, Basu N, Cid M, Ferrario F . 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012; 65(1):1-11. DOI: 10.1002/art.37715. View